Actionable news
All posts from Actionable news
Actionable news in INFI: Infinity Pharmaceuticals, Inc.,

Infinity Pharmaceuticals: Potential Catalysts? 0 comments

Final in a Series about Infinity Pharmaceuticals

Infinity Pharmaceuticals(NASDAQ:INFI) is either on sale at bargain-basement prices or is in trouble. As discussed in previous posts,Wall Street analysts seem to be pitching their tents in the "in trouble" camp. Based upon research gathered from company press releases, SEC filings, FDA/EMA approval criteria, and recent clinical trials, there may be catalysts ahead that could catapult this company's stock price to at least the $5-5.50 support established in 2016. Recent volume and price action indicate a bullish sentiment is growing for INFI.

Near-term Potential Catalyst #1:

Announcement of Submission of Global Regulatory Applications for Commercialization of Duvelisib

It's a big world. Commercialization of duvelisib could be approved more rapidly than in the U.S. in a variety of countries. For example, Infinity is involved in a Phase 3 Study of Duvelisib Versus Ofatumumab. Ofatumumab received regulatory...